News
Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...
Investor's Business Daily on MSN38m
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss BrawlIn the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback